May 25, 2012
Zeria Pharmaceutical revealed at a business briefing in Tokyo on May 23 that it is projecting sales of 12.2 billion yen (+19% compared to FY2011) for the ulcerative colitis treatment Asacol (mesalazine) for FY2012 (ending March 31, 2013). As sales...read more